HUS1500001I1 - ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére - Google Patents

ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére

Info

Publication number
HUS1500001I1
HUS1500001I1 HUS1500001C HUS1500001C HUS1500001I1 HU S1500001 I1 HUS1500001 I1 HU S1500001I1 HU S1500001 C HUS1500001 C HU S1500001C HU S1500001 C HUS1500001 C HU S1500001C HU S1500001 I1 HUS1500001 I1 HU S1500001I1
Authority
HU
Hungary
Prior art keywords
dexamethasone
combination therapy
treating cancer
cancer
treating
Prior art date
Application number
HUS1500001C
Other languages
English (en)
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of HUS1500001I1 publication Critical patent/HUS1500001I1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HUS1500001C 1999-05-13 2015-01-06 ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére HUS1500001I1 (hu)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound
PCT/GB2000/001857 WO2000069441A1 (en) 1999-05-13 2000-05-15 Compositions and uses of et743 for treating cancer
HU0201187A HU229866B1 (en) 1999-05-13 2000-05-15 Use of et743 in combination therapy with dexamethasone for treating cancer

Publications (1)

Publication Number Publication Date
HUS1500001I1 true HUS1500001I1 (hu) 2016-08-29

Family

ID=27546594

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0201187A HU229866B1 (en) 1999-05-13 2000-05-15 Use of et743 in combination therapy with dexamethasone for treating cancer
HUS1500001C HUS1500001I1 (hu) 1999-05-13 2015-01-06 ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU0201187A HU229866B1 (en) 1999-05-13 2000-05-15 Use of et743 in combination therapy with dexamethasone for treating cancer

Country Status (32)

Country Link
US (1) US8119638B2 (hu)
EP (3) EP1702618B1 (hu)
JP (2) JP2002544231A (hu)
KR (1) KR20020019914A (hu)
CN (2) CN1360503A (hu)
AR (1) AR028476A1 (hu)
AT (3) ATE375795T1 (hu)
AU (2) AU777417B2 (hu)
BG (1) BG65680B1 (hu)
BR (1) BR0010531A (hu)
CA (1) CA2373794C (hu)
CY (4) CY1105818T1 (hu)
CZ (1) CZ301482B6 (hu)
DE (4) DE60036826T2 (hu)
DK (3) DK1716853T3 (hu)
ES (2) ES2272279T3 (hu)
FR (1) FR08C0013I2 (hu)
HU (2) HU229866B1 (hu)
IL (2) IL146434A0 (hu)
LU (1) LU91418I2 (hu)
MX (1) MXPA01011562A (hu)
MY (1) MY164077A (hu)
NL (1) NL300337I2 (hu)
NO (2) NO324564B1 (hu)
NZ (1) NZ515423A (hu)
PL (1) PL198185B1 (hu)
PT (3) PT1716853E (hu)
SI (3) SI1702618T1 (hu)
SK (1) SK287580B6 (hu)
TR (1) TR200103819T2 (hu)
UA (1) UA74782C2 (hu)
WO (1) WO2000069441A1 (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CZ20031327A3 (cs) * 2000-11-06 2003-11-12 Pharma Mar, S. A. Užití ET-743 k výrobě léků pro účinnou protinádorovou léčbu
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
US20050004018A1 (en) * 2001-10-19 2005-01-06 Jose Jimeno Use of antitumoral compound in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
WO2005049031A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Combination
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
AU2005261860A1 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
JP4554684B2 (ja) * 2004-10-26 2010-09-29 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗癌治療
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2007249281A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
WO2009050303A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for et-743 treatment
US10610529B2 (en) * 2016-02-04 2020-04-07 Jiangsu Hengrui Medicine Co., Ltd. Trabectedin-inclusive injectable pharmaceutical composition for gastrointestinal external use and a method for manufacturing the same
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
KR20230002462A (ko) 2020-04-15 2023-01-05 에버 발린젝트 게엠베하 트라벡테딘 및 아미노산을 포함하는 조성물
US20230226051A1 (en) 2022-01-20 2023-07-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
ATE69234T1 (de) * 1986-06-09 1991-11-15 Univ Illinois Ekteinascidine 729, 743, 745, 759a, 759b and 770.
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
WO1994026250A1 (en) * 1993-05-14 1994-11-24 Depotech Corporation Method for treating neurological disorders
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
ATE305301T1 (de) * 1996-11-05 2005-10-15 Childrens Medical Center Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
CZ301083B6 (cs) * 1998-04-06 2009-11-04 The Board Of Trustees Of The University Of Illinois Ekteinascidinová sloucenina, farmaceutický prostredek ji obsahující a její použití
EP1077698B1 (en) * 1998-05-11 2005-03-02 Pharma Mar, S.A. Metabolites of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
MXPA02010088A (es) 2000-04-12 2004-08-19 Pharma Mar Sa Derivados de ecteinascidina antitumorales.
US7247892B2 (en) 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
CA2418320A1 (en) 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
CZ20031327A3 (cs) 2000-11-06 2003-11-12 Pharma Mar, S. A. Užití ET-743 k výrobě léků pro účinnou protinádorovou léčbu
WO2002064843A1 (en) 2001-02-09 2002-08-22 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
AU2002242561A1 (en) 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
US20050004018A1 (en) 2001-10-19 2005-01-06 Jose Jimeno Use of antitumoral compound in cancer therapy
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
WO2005049031A1 (en) 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Combination
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1691809A1 (en) 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
AU2005261860A1 (en) 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
JP2008514688A (ja) 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
JP4554684B2 (ja) 2004-10-26 2010-09-29 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗癌治療
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
EP1962843B1 (en) 2005-11-25 2011-02-23 Pharma Mar S.A., Sociedad Unipersonal Use of parp-1 inhibitors
AU2007249281A1 (en) 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
JP5777562B2 (ja) 2015-09-09
US20070275942A1 (en) 2007-11-29
EP1176964A1 (en) 2002-02-06
DE60030554T2 (de) 2007-09-13
NZ515423A (en) 2004-04-30
EP1702618A3 (en) 2006-12-27
PT1702618E (pt) 2008-01-11
SK16442001A3 (sk) 2002-03-05
HU229866B1 (en) 2014-10-28
MY164077A (en) 2017-11-30
NO20015516D0 (no) 2001-11-12
EP1176964B8 (en) 2007-10-10
LU91418I9 (hu) 2019-01-02
EP1716853B9 (en) 2011-09-28
IL146434A (en) 2008-03-20
DE60045720D1 (de) 2011-04-21
PL198185B1 (pl) 2008-06-30
AR028476A1 (es) 2003-05-14
ATE500830T1 (de) 2011-03-15
CY1105818T1 (el) 2011-02-02
DK1702618T3 (da) 2008-02-25
AU777417B2 (en) 2004-10-14
HUP0201187A3 (en) 2002-11-28
SK287580B6 (sk) 2011-03-04
FR08C0013I2 (fr) 2009-10-30
DK1176964T3 (da) 2007-01-15
CN1679631A (zh) 2005-10-12
KR20020019914A (ko) 2002-03-13
DE122008000013I1 (de) 2008-08-07
BG65680B1 (bg) 2009-06-30
CY2008007I2 (el) 2009-11-04
EP1702618B1 (en) 2007-10-17
HUP0201187A2 (en) 2002-09-28
PT1176964E (pt) 2007-01-31
LU91418I2 (fr) 2008-05-13
FR08C0013I1 (hu) 2008-05-30
NO2008005I1 (no) 2008-06-09
AU4597500A (en) 2000-12-05
TR200103819T2 (tr) 2002-04-22
SI1702618T1 (sl) 2008-02-29
NO2008005I2 (hu) 2010-09-27
UA74782C2 (uk) 2006-02-15
DK1716853T3 (da) 2011-06-27
SI1716853T1 (sl) 2011-10-28
CY1112753T1 (el) 2016-02-10
WO2000069441A1 (en) 2000-11-23
PT1716853E (pt) 2011-05-12
MXPA01011562A (es) 2002-07-30
ATE375795T1 (de) 2007-11-15
CA2373794C (en) 2005-10-11
NL300337I1 (nl) 2008-05-01
AU2005200180B2 (en) 2007-12-13
CZ301482B6 (cs) 2010-03-17
ATE338552T1 (de) 2006-09-15
CN100477993C (zh) 2009-04-15
DE60030554T8 (de) 2008-01-10
EP1702618A2 (en) 2006-09-20
US8119638B2 (en) 2012-02-21
EP1716853A2 (en) 2006-11-02
CY1107143T1 (el) 2010-07-28
JP2002544231A (ja) 2002-12-24
EP1176964B1 (en) 2006-09-06
EP1716853A3 (en) 2006-11-15
SI1176964T1 (sl) 2007-02-28
AU2005200180B9 (en) 2008-05-29
NL300337I2 (nl) 2008-09-01
CY2008007I1 (el) 2009-11-04
AU2005200180A1 (en) 2005-02-10
DE60030554D1 (de) 2006-10-19
CA2373794A1 (en) 2000-11-23
CN1360503A (zh) 2002-07-24
BR0010531A (pt) 2002-06-04
NO324564B1 (no) 2007-11-19
IL146434A0 (en) 2002-07-25
PL352931A1 (en) 2003-09-22
DE60036826T2 (de) 2008-08-28
ES2294756T3 (es) 2008-04-01
ES2272279T3 (es) 2007-05-01
NO20015516L (no) 2002-01-11
DE60036826D1 (de) 2007-11-29
JP2012149095A (ja) 2012-08-09
CZ20014081A3 (cs) 2002-11-13
BG106171A (en) 2002-06-28
EP1716853B1 (en) 2011-03-09

Similar Documents

Publication Publication Date Title
HUS1500001I1 (hu) ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére
GB2354949B (en) Apparatus for treating body tissues with electricty
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
PL329947A1 (en) Baloon catheter for use in photodynamic therapy
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
IL136167A0 (en) Conjugates useful in the treatment of prostate cancer
HK1044111A1 (en) Improved cancer treatment with temozolomide
HUP0200717A3 (en) Radioactive cisplatin in the treatment of cancer
EG22346A (en) Process for the preparation of conjugates useful in the treatment of prostate cancer
IL149281A0 (en) Treatment of cancer
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
HK1041659A1 (zh) 癌治療藥劑供給裝置
PL352681A1 (en) Preventive and therapeutic agents for cancer
GB9906130D0 (en) Compounds for use in therapy
AU4486500A (en) Therapeutic compositions and methods for treating tumors
KR100511819B1 (en) Compositions and Methods for the Treatment of Tumor
GB2388548B (en) Apparatus for treating body tissues with medicaments
AU3735100A (en) Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
GB9905307D0 (en) Therapy and use of compounds in therapy
GB9905315D0 (en) Therapy and use of compounds in therapy
KR100512820B1 (en) Compositions and Methods for the Treatment of Tumor
GB0022216D0 (en) Human FAP-a-specific antibodies for use in cancer therapy
GB9908176D0 (en) Cancer treatment
GB9927106D0 (en) Cancer treatment